-
Singde Yiyang Secures Series A Financing to Expand Wellness Services in China
•
Singde Yiyang, a leading wellness service provider based in Qingdao, reportedly raised “hundreds of millions” of renminbi in a Series A financing round led by Genertec Investment. The company plans to implement a “1+X+N” layout, covering key regions and cities in China, with a target of over 10,000 beds. Company…
-
NMPA Releases 65th Batch of Reference Drugs for Generic Quality Consistency Evaluation
•
The National Medical Products Administration (NMPA) has released the 65th batch of reference drugs for the Generic Quality Consistency Evaluation (GQCE) work. This update includes 67 new specifications, encompassing 8 injectables and 21 specifications with modifications. Details of the UpdateThe modifications in this batch involve changes and increases in marketing…
-
NHSA Launches Crackdown on Medical Insurance Fund Management with New Inspection Measures
•
The National Healthcare Security Administration (NHSA) is intensifying efforts to manage medical insurance funds at hospitals by launching a crackdown. The agency has released the “Interim and Management Measures for Unannounced Inspections of Medical Security Funds,” which will be effective as of May 1, 2023. Details of the MeasuresThe document…
-
Meinian Onehealth and Astra Biotechnology Partner on Hypersensitive Blood Biomarker Detection
•
China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with compatriot firm Astra Biotechnology Co., Ltd to develop hypersensitive blood biomarker detection capabilities. The collaboration will focus on creating a humoral biomarker detection scheme and screening model for physical examinations targeting brain diseases and other…
-
Immorna Enrolls First Patient in Phase I Study of JCXH-211 for Malignant Tumors
•
Immorna (Hangzhou) Biotechnology, an mRNA-based vaccine developer based in Hangzhou, has announced the enrollment of the first patient in a Phase I clinical study to assess the safety and efficacy of JCXH-211, a potential cancer therapeutic, in malignant solid tumors in China. The study will determine the recommended Phase II…
-
CDE Issues Guidelines on Single-Arm Clinical Trials for Antitumor Drugs
•
The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for the Applicability of Single-arm Clinical Trials to Support the Market Filing for Antitumor Drugs.” The document provides clarity on the limitations of single-arm clinical trials, their applicability, and the requirements for confirmatory clinical trials in support of both…
-
XtalPi and DP Technology Partner to Accelerate Pre-Clinical Drug Development with AI
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a partnership with Beijing-based DP Technology. The collaboration aims to leverage DP Tech’s AI for Science computation platform and XtalPi’s intelligent, automatic drug research and development (R&D) solutions to streamline the pre-clinical drug R&D process, thereby accelerating drug development. XtalPi’s…
-
Laekna Therapeutics Files for IPO on Hong Kong Stock Exchange, Aims to Expand Cancer and Hepatic Fibrosis Therapies
•
China’s Laekna Therapeutics Shanghai Co., Ltd has filed for an initial public offering (IPO) with the Hong Kong Stock Exchange (HKSE), according to the exchange. The offering will be sponsored by CICC. This move marks a significant step in Laekna’s growth strategy as it seeks to raise capital to further…
